| ADNRX | RPTIX | ADNRX / RPTIX | |
| Total Expense Ratio | 1.00 | 0.63 | 159% |
| Annual Report Gross Expense Ratio | 1.13 | 0.63 | 179% |
| Fund Existence | 5 years | 10 years | - |
| Gain YTD | 35.792 | 3.369 | 1,063% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 500000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 202M | 25.9B | 1% |
| Annual Yield % from dividends | 0.00 | 0.05 | - |
| Returns for 1 year | 38.28 | -8.70 | -440% |
| Returns for 3 years | 83.45 | 10.44 | 799% |
| Returns for 5 years | -42.54 | -6.04 | 704% |
| Returns for 10 years | N/A | 31.48 | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AMDG | 45.02 | 6.83 | +17.88% |
| Leverage Shares 2X Long AMD Daily ETF | |||
| HQL | 16.98 | 0.22 | +1.31% |
| abrdn Life Sciences Investors | |||
| BTA | 9.56 | 0.01 | +0.10% |
| Blackrock Long-Term Municipal Advantage Trust | |||
| JMST | 50.92 | 0.01 | +0.02% |
| JPMorgan Ultra-Short Municipal Inc ETF | |||
| HELX | 34.90 | N/A | N/A |
| Franklin Genomic Advancements ETF | |||